

FEB 04 2011

**INSIGHT BIOTEK INC.**

TO: USPTO  
Attention: Patricia Duffy  
FAX#: 571-273-8300  
DATE: Feb 4, 2011

FROM: Diane Van Alstyne  
FAX #:  
PHONE #: 250-493-3793  
# OF PAGES: 1 REF: ✓

Re: Application of van Alstyne, et al.

Application No. 09/489,850

**METHODS TO CLEAR MENINGITIS-CAUSING AGENTS USING ANTIBODIES TO PEPTIDES  
REPRESENTING EPITOPIC SITES FOR BACTERIAL AND VIRAL MENINGITIS CAUSING AGENTS**

Insight Biotek has 2 issued patents (5,510,264 & 5,556,757) describing a common antigen found in all meningitis-causing organisms tested.

Our attorneys, Foley and Lardner, filed 2 applications of this work to the treatment and prevention of meningitis:  
No. 08/988,444 - data describing use of our monoclonal antibodies as therapeutics, and  
No. 09/489,850 - data describing the use of our peptide antigens in a novel, universal vaccine.

My understanding has been that the '444 application has been permanently abandoned.


On reading the most recent office action of December 20, 2010, I see that data from the '444 application has mistakenly been included in the vaccine application, '850.

Foley and Lardner has terminated our business with them and returned our records from Washington. Now I see that the petition that you reviewed was a jumble of data from both applications and that the petition with the new claim set was never returned to me from their Chicago office which drafted the most recent submission.


This makes it difficult to reply to the office action. I have left a phone message with Patricia Duffy's office and hope to discuss this with her.

We are happy to comply with the examiner's requests and will do everything in our power to complete this application as soon as possible.

Please advise.



Diane Van Alstyne



Date